The first diagnostic test to classify cancers by differences in microRNAs–small pieces of RNA that regulate genes–will soon be on the market. The test distinguishes two types of lung cancer and should help doctors tailor treatments to their patients’ needs. Scientists say that tests based on microRNA profiles could prove more sensitive and reliable than existing methods, whose accuracy depends heavily on the judgment of the people analyzing them.
Product: MicroRNA test for lung cancer
Cost: Comparable to that of other molecular tests for cancer, which are priced at around $3,000 to $3,500
Company: Rosetta Genomics
Subscribe to Continue Reading
Uh oh–you've read all five of your free articles for this month.
Insider Online Only
$19.95/yr US PRICE
High-Speed Video Footage Solves One of the Great Mysteries of Human Blood Flow
A key theory of blood dynamics has been overturned by video evidence showing how red blood cells can make blood less viscous.
The Unintended Consequence of Congress’s Ban on Designer Babies
The testing of new therapies to prevent a debilitating mitochondrial genetic disease in babies has hit a dead end.
How the Mathematics of Algebraic Topology Is Revolutionizing Brain Science
Nobody understands the brain’s wiring diagram, but the tools of algebraic topology are beginning to tease it apart.